NASDAQ:IRON

Disc Medicine (IRON) Stock Price, News & Analysis

$32.18
+0.26 (+0.81%)
(As of 05/17/2024 ET)
Today's Range
$31.44
$32.48
50-Day Range
$26.52
$67.64
52-Week Range
$25.60
$77.60
Volume
376,432 shs
Average Volume
404,373 shs
Market Capitalization
$794.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.71

Disc Medicine MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
79.3% Upside
$57.71 Price Target
Short Interest
Healthy
12.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Disc Medicine in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$81,408 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.67) to ($5.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.27 out of 5 stars

Medical Sector

325th out of 922 stocks

Pharmaceutical Preparations Industry

148th out of 427 stocks

IRON stock logo

About Disc Medicine Stock (NASDAQ:IRON)

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

IRON Stock Price History

IRON Stock News Headlines

Cantor Fitzgerald Keeps Their Buy Rating on Disc Medicine (IRON)
See More Headlines
Receive IRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
5/17/2024
Next Earnings (Estimated)
8/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IRON
Fax
N/A
Employees
74
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$57.71
High Stock Price Target
$85.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+79.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-76,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$13.70 per share

Miscellaneous

Free Float
23,635,000
Market Cap
$794.20 million
Optionable
Not Optionable
Beta
0.44
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. William Jacob Savage M.D. (Age 49)
    Ph.D., Chief Medical Officer
    Comp: $687.74k
  • Dr. John D. Quisel Esq. (Age 53)
    J.D., Ph.D., CEO, President & Director
    Comp: $750.12k
  • Dr. Brian MacDonald ChB (Age 64)
    MB, Ph.D., Founder & Chair of Scientific Advisory Board
    Comp: $88.54k
  • Ms. Jean M. Franchi (Age 58)
    Chief Financial Officer
  • Mr. Jonathan Yu M.B.A. (Age 43)
    Chief Opearating Officer
    Comp: $539.32k
  • Dr. Rahul Khara J.D. (Age 42)
    Pharm.D., General Counsel, Compliance Officer & Secretary
  • Mr. Srikanth Venkatraman Ph.D.
    Senior VP & Head of Chemistry
  • Ms. Hua Yang Ph.D.
    Senior Vice President of Nonclinical Development
  • Ms. Pamela Stephenson M.P.H. (Age 55)
    Chief Commercial Officer
  • Ms. Sonia Razzetti Ph.D.
    Senior VP of Quality

IRON Stock Analysis - Frequently Asked Questions

Should I buy or sell Disc Medicine stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Disc Medicine in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IRON shares.
View IRON analyst ratings
or view top-rated stocks.

What is Disc Medicine's stock price target for 2024?

7 Wall Street analysts have issued twelve-month price targets for Disc Medicine's stock. Their IRON share price targets range from $40.00 to $85.00. On average, they expect the company's share price to reach $57.71 in the next year. This suggests a possible upside of 79.3% from the stock's current price.
View analysts price targets for IRON
or view top-rated stocks among Wall Street analysts.

How have IRON shares performed in 2024?

Disc Medicine's stock was trading at $57.76 on January 1st, 2024. Since then, IRON shares have decreased by 44.3% and is now trading at $32.18.
View the best growth stocks for 2024 here
.

When is Disc Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our IRON earnings forecast
.

How were Disc Medicine's earnings last quarter?

Disc Medicine, Inc. (NASDAQ:IRON) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by $0.22.

Who are Disc Medicine's major shareholders?

Disc Medicine's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (9.47%), Bain Capital Life Sciences Investors LLC (5.34%), Price T Rowe Associates Inc. MD (3.83%), Vanguard Group Inc. (3.24%), Janus Henderson Group PLC (2.11%) and Ikarian Capital LLC (0.00%). Insiders that own company stock include Brian Richard Macdonald, Holdings A/S Novo, Joanne Bryce, Kevin Bitterman, Mona Ashiya, Orbimed Advisors Llc, Rahul Khara, Venture Fund X LP Atlas, William Jacob Savage and William Richard White.
View institutional ownership trends
.

How do I buy shares of Disc Medicine?

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRON) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners